

CITATION REPORT

List of articles citing

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

DOI: 10.1016/j.jchf.2013.10.006

JACC: Heart Failure, 2014, 2, 97-112.

Source: <https://exaly.com/paper-pdf/58908113/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|----|-----------|
| 246 | Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. 2014 , 7, 1042-9 | | 73 |
| 245 | Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology. 2014 , 109, 450 | | 32 |
| 244 | Deleting titin β I-band/A-band junction reveals critical roles for titin in biomechanical sensing and cardiac function. 2014 , 111, 14589-94 | | 61 |
| 243 | The heart failure paradox: an epidemic of scientific success. Presidential Address at the American Heart Association 2013 Scientific Sessions. 2014 , 129, 2717-22 | | 8 |
| 242 | Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin". 2015 , 132, e248 | | |
| 241 | Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. 2015 , 17, 760-3 | | 14 |
| 240 | Geographic differences in heart failure trials. 2015 , 17, 893-905 | | 53 |
| 239 | Reclassifying heart failure: time for disruptive innovation?. 2015 , 17, 879-80 | | 3 |
| 238 | Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. 2015 , 17, 1231-9 | | 59 |
| 237 | Heart Failure With Preserved Ejection Fraction. 2015 , 115, 432-42 | | 9 |
| 236 | Heart failure with preserved ejection fraction: refocusing on diastole. 2015 , 179, 430-40 | | 73 |
| 235 | Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. 2015 , 131, 34-42 | | 534 |
| 234 | The aging heart, endothelin-1 and the senescent cardiac fibroblast. 2015 , 81, 12-4 | | 5 |
| 233 | The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. 2015 , 20, 291-303 | | 75 |
| 232 | Diastolische Herzinsuffizienz. 2015 , 9, 315-328 | | |
| 231 | Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. 2015 , 36, 2585-94 | | 470 |
| 230 | Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. 2015 , 21, 719-29 | | 38 |

| | | | |
|-----|--|-----|------------------|
| 229 | Creation of clinically relevant model of chronic heart failure: Application of multi-modality imaging to define physiology. 2015 , 22, 673-6 | | |
| 228 | Diastolic dysfunction in chronic hypoxia: IL-18 provides the elusive link. 2015 , 213, 298-300 | | 0 |
| 227 | Heart failure with preserved ejection fraction: uncertainties and dilemmas. 2015 , 17, 665-71 | | 97 |
| 226 | Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. 2015 , 2, e000260 | | 13 |
| 225 | EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4. 2015 , 56, 2297-308 | | 30 |
| 224 | International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 2015 , 131, 43-53 | | 58 |
| 223 | Reasonable expectations: how much aerobic capacity, muscle strength, and quality of life can improve with exercise training in heart failure. <i>Heart Failure Clinics</i> , 2015 , 11, 37-57 | 3-3 | 10 |
| 222 | Amyloid Light-Chain Amyloidosis Manifesting as Heart Failure with Preserved Ejection Fraction in a Patient with Hyper-Immunoglobulin E-emia. 2016 , 17, 235-40 | | 3 |
| 221 | T1 and ECV Mapping in Myocardial Disease. 2016 , 2, 73-84 | | |
| 220 | Pluripotent Stem Cells: Current Understanding and Future Directions. 2016 , 2016, 9451492 | | 60 |
| 219 | Targeting heart failure with preserved ejection fraction: current status and future prospects. 2016 , 12, 129-41 | | 19 |
| 218 | Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. 2017 , 243, 79-108 | | 4 |
| 217 | Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. 2016 , 7, 13710 | | 118 |
| 216 | Ivabradine: Role in the Chronic Heart Failure Armamentarium. 2016 , 133, 2066-75 | | 20 |
| 215 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016 , 37, 2129-2200 | | 775 ¹ |
| 214 | Isolation of Cardiomyocytes and Cardiac Fibroblasts for Ex Vivo Analysis. <i>Methods in Molecular Biology</i> , 2016 , 1419, 117-29 | 1.4 | 1 |
| 213 | Developing New Treatments for Heart Failure: Focus on the Heart. 2016 , 9, | | 41 |
| 212 | Unmet Needs and Prioritization in Heart Failure. 2016 , 22, 587-8 | | 2 |

| | | |
|-----|---|------|
| 211 | Amiloidosis cardiaca por transtiretina: antes una enfermedad monogénica minoritaria, ¿ahora una vñ comñ en la insuficiencia cardiaca?. 2016 , 69, 888-889 | 1 |
| 210 | Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. 2016 , 18, 54-65 | 57 |
| 209 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016 , 18, 891-975 | 4036 |
| 208 | Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (Ttn ^{ΔAjxn}). 2016 , 119, 764-72 | 20 |
| 207 | Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants. 2016 , 18, 1287-1297 | 11 |
| 206 | Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. 2016 , 9, | 25 |
| 205 | Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction. 2016 , 9, | 66 |
| 204 | Transthyretin Cardiac Amyloidosis: From Rare Monogenic Disease to Common Pathway in Heart Failure?. 2016 , 69, 888-889 | 2 |
| 203 | Clinical Trial Design, Endpoints, and Regulatory Requirements. 2017 , 243, 67-78 | 3 |
| 202 | The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. 2017 , 38, 473-477 | 81 |
| 201 | Myocardial reverse remodeling: how far can we rewind?. 2016 , 310, H1402-22 | 23 |
| 200 | Coronary flow reserve as a link between exercise capacity, cardiac systolic and diastolic function. 2016 , 217, 161-6 | 14 |
| 199 | Relaxin-2 improves diastolic function of pressure-overloaded rats via phospholamban by activating Akt. 2016 , 218, 305-311 | 10 |
| 198 | Factors affecting left ventricular function: The new era of the Hellenic Journal of Cardiology in Elsevier group. 2016 , 57, 71-2 | 3 |
| 197 | Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. 2016 , 102, 257-9 | 43 |
| 196 | Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. 2016 , 9, | 68 |
| 195 | Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. 2016 , 37, 455-62 | 217 |
| 194 | Heart Failure Prevention: Special Considerations for Women. 2016 , 10, 1 | |

| | | |
|-----|--|-----|
| 193 | A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. 2016 , 387, 1298-304 | 166 |
| 192 | Prognosis for Women With Multivessel Coronary Artery Disease. 2016 , 67, 705-8 | |
| 191 | Impact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis). 2016 , 117, 1474-81 | 35 |
| 190 | From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. 2016 , 102, 320-30 | 17 |
| 189 | Mesenchymal stem cell-derived inflammatory fibroblasts mediate interstitial fibrosis in the aging heart. 2016 , 91, 28-34 | 31 |
| 188 | La fracci3n de eyecci3n intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca. 2017 , 70, 338-346 | 34 |
| 187 | The Diabetic Heart Failure With Preserved Ejection Fraction Phenotype: Is it Real and Is It Worth Targeting Therapeutically?. 2017 , 135, 736-740 | 20 |
| 186 | Clinical diagnosis of heart failure in nursing home residents based on history, physical exam, BNP and ECG: Is it reliable?. 2017 , 8, 59-65 | 2 |
| 185 | Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. 2017 , 18, 399-409 | 11 |
| 184 | Fracci3n de eyecci3n del ventr3culo izquierdo de pacientes con insuficiencia cardiaca aguda: ¿un marcador dBil?. 2017 , 70, 318-319 | 1 |
| 183 | Microparticles in Chronic Heart Failure. 2017 , 81, 1-41 | 9 |
| 182 | Comorbidities in heart failure with mid-range ejection fraction. 2017 , 41, e27-e28 | 0 |
| 181 | Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. 2017 , 14, 59-70 | 38 |
| 180 | Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch-induced activation. 2017 , 35, 602-611 | 17 |
| 179 | Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings. 2017 , 23, 517-524 | 13 |
| 178 | HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. 2017 , 228, 709-716 | 27 |
| 177 | Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. 2017 , 10, | 33 |
| 176 | Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heArT failure patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. 2017 , 19, 782-791 | 54 |

| | | | |
|-----|--|-----|-----|
| 175 | Differences in Repolarization Heterogeneity Among Heart Failure With Preserved Ejection Fraction Phenotypic Subgroups. 2017 , 120, 601-606 | | 10 |
| 174 | Influence of renal dysfunction phenotype on mortality in decompensated heart failure with preserved and mid-range ejection fraction. 2017 , 243, 332-339 | | 5 |
| 173 | Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. 2017 , 217, 398-404 | | |
| 172 | Left Ventricular Ejection Fraction in Patients With Acute Heart Failure: A Limited Tool?. 2017 , 70, 318-319 | | |
| 171 | Remote Monitoring in Heart Failure: the Current State. 2017 , 19, 22 | | 4 |
| 170 | Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. 2017 , 33, 768-776 | | 8 |
| 169 | Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. 2017 , 19, 1574-1585 | | 301 |
| 168 | Serelaxin in clinical development: past, present and future. 2017 , 174, 921-932 | | 22 |
| 167 | Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart Failure. 2017 , 70, 338-346 | | 19 |
| 166 | n-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. 2017 , 103, 74-92 | | 40 |
| 165 | Exercise Training Reveals Inflexibility of the Diaphragm in an Animal Model of Patients With Obesity-Driven Heart Failure With a Preserved Ejection Fraction. 2017 , 6, | | 29 |
| 164 | Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. 2017 , 19, 1690-1697 | | 19 |
| 163 | Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. <i>JACC: Heart Failure</i> , 2017 , 5, 763-771 | 7.9 | 103 |
| 162 | Heart Failure With Preserved Ejection Fraction: A Perioperative Review. 2017 , 31, 1820-1830 | | 7 |
| 161 | The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update. 2017 , 10, 1056-1071 | | 13 |
| 160 | Complement and contact system activation in acute congestive heart failure patients. 2017 , 190, 251-257 | | 4 |
| 159 | Insuficiencia cardíaca. Generalidades. 2017 , 12, 2085-2091 | | 1 |
| 158 | Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. 2017 , 217, 398-404 | | 1 |

| | | | |
|-----|---|-----|----|
| 157 | Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. <i>ESC Heart Failure</i> , 2017 , 4, 432-439 | 3.7 | 28 |
| 156 | Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance. 2017 , 10, | | 13 |
| 155 | Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. 2017 , 10, 322-336 | | 27 |
| 154 | HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. 2017 , 23, 293-303 | | 21 |
| 153 | Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. 2018 , 114, 782-793 | | 30 |
| 152 | Left Ventricular Diastolic Function After Aortic Valve Replacement for Chronic Aortic Regurgitation. 2018 , 106, 24-29 | | 6 |
| 151 | Interatrial Shunting, a Novel Device-Based Therapy for Patients With Heart Failure. 2018 , 26, 267-273 | | 1 |
| 150 | Methods to identify heart failure patients in general practice and their impact on patient characteristics: A systematic review. 2018 , 257, 199-206 | | 7 |
| 149 | Relative Impairments in Hemodynamic Exercise Reserve Parameters in Heart Failure With Preserved Ejection Fraction: A Study-Level Pooled Analysis. <i>JACC: Heart Failure</i> , 2018 , 6, 117-126 | 7.9 | 23 |
| 148 | Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. 2018 , 114, 954-964 | | 96 |
| 147 | Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. 2018 , 3, 288-297 | | 52 |
| 146 | Mortality after an episode of acute heart failure in a cohort of patients with intermediate ventricular function: Global analysis and relationship with admission department. 2018 , 151, 223-230 | | 3 |
| 145 | Left ventricular ejection fraction and heart failure: an indissoluble marriage?. 2018 , 20, 427-430 | | 27 |
| 144 | Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose. 2018 , 18, 57 | | 15 |
| 143 | Comorbidities and Cardiometabolic Disease: Relationship With Longitudinal Changes in Diastolic Function. <i>JACC: Heart Failure</i> , 2018 , 6, 317-325 | 7.9 | 12 |
| 142 | Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. 2018 , 121, 1558-1566 | | 8 |
| 141 | The Current Focus of Heart Failure Clinical Trials. 2018 , 24, 321-329 | | 2 |
| 140 | Reduced Myocardial Flow Reserve Is Associated With Diastolic Dysfunction and Decreased Left Atrial Strain in Patients With Normal Ejection Fraction and Epicardial Perfusion. 2018 , 24, 90-100 | | 20 |

| | | | |
|-----|---|-----|----|
| 139 | Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. 2018 , 20, 815-816 | | 5 |
| 138 | Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction. 2018 , 104, 525-532 | | 26 |
| 137 | Sleep disordered breathing in older adults with heart failure with preserved ejection fraction. 2018 , 39, 77-83 | | 2 |
| 136 | Guideline-Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient-Pooled Analysis From the Kor HF and Kor AHF Registries. 2018 , 7, e009806 | | 17 |
| 135 | Estradiol Treatment Initiated Early After Ovariectomy Regulates Myocardial Gene Expression and Inhibits Diastolic Dysfunction in Female Cynomolgus Monkeys: Potential Roles for Calcium Homeostasis and Extracellular Matrix Remodeling. 2018 , 7, e009769 | | 17 |
| 134 | Skeletal Muscle Myopathy in Heart Failure: the Role of Ejection Fraction. 2018 , 20, 116 | | 5 |
| 133 | Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial. 2018 , 7, e009664 | | 13 |
| 132 | What is Heart Failure with Mid-range Ejection Fraction? A New Subgroup of Patients with Heart Failure. <i>Cardiac Failure Review</i> , 2018 , 4, 6-8 | 4.2 | 11 |
| 131 | Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group?. 2018 , 21, 1-6 | | 9 |
| 130 | Effects of Endurance Training on Detrimental Structural, Cellular, and Functional Alterations in Skeletal Muscles of Heart Failure With Preserved Ejection Fraction. 2018 , 24, 603-613 | | 13 |
| 129 | Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction. 2018 , 18, 104 | | 10 |
| 128 | Mortality after an episode of acute heart failure in a cohort of patients with intermediate ventricular function: Global analysis and relationship with admission department. 2018 , 151, 223-230 | | |
| 127 | Left atrial strain: measurement and clinical application. 2018 , 33, 479-485 | | 24 |
| 126 | Benefit-risk review of different drug classes used in chronic heart failure. 2019 , 18, 37-49 | | 5 |
| 125 | Particularities of Older Patients with Obstructive Sleep Apnea and Heart Failure with Mid-Range Ejection Fraction. 2019 , 55, | | 2 |
| 124 | Mid-regional pro-atrial natriuretic peptide for diagnosis of heart failure in non-acute settings: biomarkers plus clinical sense make good sense. 2019 , 21, 1228-1230 | | 1 |
| 123 | Vagus nerve stimulation for the treatment of heart failure. 2019 , 2, 43-54 | | 2 |
| 122 | Sex Differences in Long-Term Clinical Outcomes in Patients Hospitalized for Acute Heart Failure: A Report from the Korean Heart Failure Registry. 2019 , 28, 1606-1613 | | 3 |

| | | | |
|-----|---|-----|----|
| 121 | Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. 2019 , 14, e0218983 | | 6 |
| 120 | Isolated Mitral Valve Repair in Patients with Reduced Left Ventricular Ejection Fraction. 2019 , 25, 326-335 | | 2 |
| 119 | Risk Factors And Epigenetic Markers Of Left Ventricular Diastolic Dysfunction With Preserved Ejection Fraction In A Community-Based Elderly Chinese Population. 2019 , 14, 1719-1728 | | 2 |
| 118 | CMR Tissue Characterization in Patients with HFmrEF. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 13 |
| 117 | A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure. 2019 , 60, 1123-1130 | | 6 |
| 116 | Role of the lysyl oxidase enzyme family in cardiac function and disease. 2019 , 115, 1820-1837 | | 17 |
| 115 | In Vivo and In Vitro Effects of Vasopressin V2 Receptor Antagonism on Myocardial Fibrosis in Rats. 2019 , 357, 151-159 | | |
| 114 | Oral Chinese Herbal Medicine for Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. 2019 , 25, 770-777 | | 2 |
| 113 | Treatment Challenges in Patients with Acute Heart Failure and Severe Aortic Valve Stenosis. 2019 , 21, 47 | | 3 |
| 112 | Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial. <i>ESC Heart Failure</i> , 2019 , 6, 613-620 | 3.7 | 10 |
| 111 | Periostin Reexpression in Heart Disease Contributes to Cardiac Interstitial Remodeling by Supporting the Cardiac Myofibroblast Phenotype. 2019 , 1132, 35-41 | | 9 |
| 110 | Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: the Henry Ford Exercise Testing (FIT) Project. 2019 , 15, 350-358 | | 9 |
| 109 | Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry. 2019 , 49, 238-248 | | 6 |
| 108 | Generalizability and Implications of the HFPEF Score in a Cohort of Patients With Heart Failure With Preserved Ejection Fraction. 2019 , 139, 1851-1853 | | 20 |
| 107 | Heart Failure with Preserved Ejection Fraction: Current Management and Future Strategies. 2019 , 335-348 | | |
| 106 | Left Ventricular Size and Ejection Fraction: Are They Still Relevant?. <i>Heart Failure Clinics</i> , 2019 , 15, 147-158 | | 4 |
| 105 | Insuficiencia cardíaca crónica. 2019 , 12, 5414-5426 | | |
| 104 | Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015. 2019 , 21, 1329-1337 | | 51 |

| | | |
|-----|---|----|
| 103 | Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction. 2019 , 18, 195-199 | 7 |
| 102 | Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40. 2019 , 98, e17296 | 2 |
| 101 | Ageing, demographics, and heart failure. 2019 , 21, L4-L7 | 17 |
| 100 | Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction. 2019 , 1865, 230-242 | 21 |
| 99 | Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans. 2019 , 12, 221-230 | 26 |
| 98 | New drugs in preclinical and early stage clinical development in the treatment of heart failure. 2019 , 28, 51-71 | 12 |
| 97 | Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction. 2019 , 104, 28-38 | 25 |
| 96 | Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. 2020 , 26, 673-684 | 2 |
| 95 | Characteristics and outcomes of HFpEF with declining ejection fraction. 2020 , 109, 225-234 | 18 |
| 94 | sST2 as a value-added biomarker in heart failure. 2020 , 501, 120-130 | 20 |
| 93 | Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. 2020 , 22, 148-158 | 68 |
| 92 | Association between systolic ejection time and outcomes in heart failure by ejection fraction. 2020 , 22, 1174-1182 | 10 |
| 91 | Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance. 2020 , 25, 75-84 | 3 |
| 90 | The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction. 2020 , 26, 100451 | 3 |
| 89 | Chronic heart failure. 2020 , 153-168 | |
| 88 | Effect of Praliquat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. 2020 , 324, 1522-1531 | 39 |
| 87 | Non-invasive vagus nerve stimulation attenuates proinflammatory cytokines and augments antioxidant levels in the brainstem and forebrain regions of Dahl salt sensitive rats. 2020 , 10, 17576 | 4 |
| 86 | Effect of Progression of Valvular Calcification on Left Ventricular Structure and Frequency of Incident Heart Failure (from the Multiethnic Study of Atherosclerosis). 2020 , 134, 99-107 | 3 |

| | | | |
|----|---|-----|----|
| 85 | The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. 2020 , 319, H765-H774 | | 3 |
| 84 | Mapping the Kansas City Cardiomyopathy Questionnaire (KCCQ) Onto EQ-5D-3L in Heart Failure Patients: Results for the Japanese and UK Value Sets. 2020 , 5, 2381468320971606 | | |
| 83 | Are there gender differences in the association between body mass index and left ventricular diastolic function? A clinical observational study in the Japanese general population. 2020 , 37, 1749-1756 | | 0 |
| 82 | Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. <i>ESC Heart Failure</i> , 2020 , 7, 1534-1546 | 3-7 | 9 |
| 81 | Rationale, design and baseline characteristics of the MyoVasc study: A prospective cohort study investigating development and progression of heart failure. 2020 , 2047487320926438 | | 5 |
| 80 | Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 1039-1048 | 3-7 | 5 |
| 79 | Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. 2020 , 16, 227-236 | | 8 |
| 78 | Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. <i>ESC Heart Failure</i> , 2020 , 7, 381-399 | 3-7 | 17 |
| 77 | Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. 2020 , 106, 342-349 | | 38 |
| 76 | Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction. 2021 , 117, 1325-1338 | | 7 |
| 75 | Prognostic value of multiple cardiac magnetic resonance imaging parameters in patients with idiopathic dilated cardiomyopathy. 2021 , 325, 89-95 | | 2 |
| 74 | Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. 2021 , 133, 125-139 | | 3 |
| 73 | The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. <i>Heart Lung and Circulation</i> , 2021 , 30, 683-691 | 1.8 | 11 |
| 72 | The predictive value of global longitudinal strain in patients with heart failure mid-range ejection fraction. 2021 , 77, 509-516 | | 1 |
| 71 | Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 2021 , 110, 1234-1248 | | 3 |
| 70 | Abnormal skeletal muscle blood flow, contractile mechanics and fibre morphology in a rat model of obese-HFpEF. 2021 , 599, 981-1001 | | 6 |
| 69 | A diastolic dysfunction model in non-human primates with transverse aortic constriction. 2021 , 70, 498-507 | | 0 |
| 68 | A comparative analysis of premature heart disease- and cancer-related mortality in women in the USA, 1999-2018. 2021 , | | 12 |

| | | | |
|----|--|-----|---|
| 67 | Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 0 |
| 66 | β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction. 2021 , | | 3 |
| 65 | Study of correlation between 2D echocardiographic assessment of right ventricle and outcome of acute heart failure patients. 2021 , 7, e06807 | | |
| 64 | Association Between Physical Status and the Effects of Combination Therapy With Renin-Angiotensin System Inhibitors and β-blockers in Patients With Acute Heart Failure. 2021 , 3, 217-226 | | 0 |
| 63 | A double-blinded, placebo-controlled randomized trial evaluating the efficacy and safety of Zhigancao Tang granules for treating HFpEF: study protocol for a randomized controlled trial. 2021 , 22, 293 | | 1 |
| 62 | Heart Failure with Supra-normal Left Ventricular Ejection Fraction - State of the Art. 2021 , 116, 1019-1022 | | 0 |
| 61 | Developmental and lifelong dioxin exposure induces measurable changes in cardiac structure and function in adulthood. 2021 , 11, 10378 | | |
| 60 | Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. 2021 , 146, 36-47 | | 7 |
| 59 | Clinical profile and causes of death according to ejection fraction in patients with heart failure cared for in a specialized Cardiology unit.. 2022 , 222, 152-160 | | |
| 58 | Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis. 2021 , 8, 657067 | | 1 |
| 57 | The Role of HECT-Type E3 Ligase in the Development of Cardiac Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 3 |
| 56 | Novel factors that activate and deactivate cardiac fibroblasts: A new perspective for treatment of cardiac fibrosis. 2021 , 29, 667-677 | | 2 |
| 55 | MiR-125b inhibits cardiomyocyte apoptosis by targeting BAK1 in heart failure. 2021 , 27, 72 | | 2 |
| 54 | Targeting fibrosis in the failing heart with nanoparticles. 2021 , 174, 461-481 | | 5 |
| 53 | Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial. 2021 , 1 | | 2 |
| 52 | Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. 2021 , 24, 1435-1445 | | 0 |
| 51 | Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. 2021 , 172, 105859 | | 6 |
| 50 | Perfil clínico y causas de muerte de los pacientes con insuficiencia cardíaca atendidos en una unidad especializada de Cardiología según su fracción de eyección. 2021 , | | 0 |

| | | | |
|----|--|-----|---|
| 49 | Sex differences in the incidence and mode of death in rats with heart failure with preserved ejection fraction. 2021 , 106, 673-682 | | 2 |
| 48 | High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction. 2021 , 13, | | 2 |
| 47 | Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction. 2020 , 49, 495-500 | | 1 |
| 46 | A Case Demonstrating the Cardio-Vascular Interaction by a New Cardio-Ankle Vascular Index During the Treatment of Concentric Hypertrophy. <i>Cardiology Research</i> , 2019 , 10, 54-58 | 1.8 | 1 |
| 45 | Aging-related Changes in Cardiac Extracellular Matrix: Implications for Heart Failure in Older Patients. <i>Journal of Cardiology & Current Research</i> , 2015 , 3, | 0.1 | 2 |
| 44 | Gaps in the Heart Failure Guidelines. <i>Cardiac Failure Review</i> , 2015 , 1, 50-55 | 4.2 | 1 |
| 43 | Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2019 , 5, 130-132 | 4.2 | 2 |
| 42 | Gaps in the Heart Failure Guidelines. <i>European Cardiology Review</i> , 2014 , 9, 104-109 | 3.9 | 2 |
| 41 | Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2018 , 34, 161-165 | 1.3 | 8 |
| 40 | The association of presystolic wave with subclinical left-ventricular dysfunction in patients with subclinical hypothyroidism. <i>Journal of Echocardiography</i> , 2021 , 1 | 1.6 | 1 |
| 39 | Stem Cells for Drug Screening. <i>Pancreatic Islet Biology</i> , 2016 , 15-41 | 0.4 | |
| 38 | Acute Heart Failure Syndromes. 2017 , 81-162 | | |
| 37 | Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). 2017 , 273-339 | | |
| 36 | Pulmonary Hypertension in Left Heart Disease. 2017 , 341-369 | | |
| 35 | HEART FAILURE IN SYSTEMIC LUPUS ERYTHEMATOSUS: RISK FACTORS AND DIAGNOSTIC FEATURES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2018 , 56, 380-385 | 0.9 | |
| 34 | «Grey zone» of heart failure. <i>Kazan Medical Journal</i> , 2018 , 99, 651-656 | 0.2 | |
| 33 | THE IMPORTANCE OF THE DIASTOLIC DYSFUNCTION IN THE CARDIOVASCULAR RISK STRATIFICATION OF NON-CARDIAC SURGICAL INTERVENTION. <i>Translational Medicine</i> , 2018 , 5, 18-25 | 0.3 | |
| 32 | Patterns of Treatment in Patients with Heart Failure with Preserved Ejection Fraction: the REasons for Geographic And Racial Differences in Stroke study. | | |

| | | | |
|----|--|------|----|
| 31 | Sleep-disordered Breathing in Heart Failure: A Complex Bidirectional Pathophysiology. <i>Indian Journal of Sleep Medicine</i> , 2019 , 14, 70-75 | 0.3 | 1 |
| 30 | Oxidative Stress and Heart Failure. 2019 , 257-311 | | 0 |
| 29 | Cardiac MRI Assessment of Mouse Myocardial Infarction and Regeneration. <i>Methods in Molecular Biology</i> , 2021 , 2158, 81-106 | 1.4 | |
| 28 | Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13401 | 4.6 | 1 |
| 27 | Sleep apnea syndrome and heart failure mechanisms and consequences. <i>Pneumologia</i> , 2019 , 68, 61-67 | 0.1 | |
| 26 | Torsional Dynamics and 2D Speckle Tracking in Heart Failure with Reduced Ejection Fraction on Patients Taking Sacubitril/Valsartan and Naive. <i>World Journal of Cardiovascular Diseases</i> , 2020 , 10, 294-304 | 0.4 | |
| 25 | Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?. <i>Cureus</i> , 2020 , 12, e7323 | 1.2 | |
| 24 | Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure Snapshot. <i>Heart Lung and Circulation</i> , 2021 , | 1.8 | 1 |
| 23 | [Characteristics and one-year outcomes in elderly patients hospitalised with heart failure and preserved, mid-range and reduced ejection fraction]. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2020 , 55, 195-200 | 1.7 | 0 |
| 22 | The human subject: an integrative animal model for 21(st) century heart failure research. <i>American Journal of Translational Research (discontinued)</i> , 2015 , 7, 1636-47 | 3 | 10 |
| 21 | Correlation Between Liver Stiffness and Diastolic Function, Left Ventricular Hypertrophy, and Right Cardiac Function in Patients With Ejection Fraction Preserved Heart Failure.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 748173 | 5.4 | 1 |
| 20 | Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.. <i>American Journal of Therapeutics</i> , 2021 , 29, e199-e204 | 1 | 1 |
| 19 | SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?. <i>Journal of Clinical Investigation</i> , 2021 , 131, | 15.9 | 0 |
| 18 | The impact of asymptomatic ventricular arrhythmias on the outcome of heart failure patients with reduced ejection fraction.. <i>Egyptian Heart Journal</i> , 2022 , 74, 11 | 1.3 | 0 |
| 17 | His Bundle Pacing Improves Left Ventricular Diastolic Function in Patients with Heart Failure with Preserved Systolic Function. <i>HeartRhythm Case Reports</i> , 2022 , | 1 | 0 |
| 16 | Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction. <i>ESC Heart Failure</i> , | 3.7 | 0 |
| 15 | Clinical Implications of Heart Rate Control in Heart Failure With Atrial Fibrillation: Multi-Center Prospective Observation Registry (CODE-AF Registry).. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 787869 | 5.4 | |
| 14 | Serum-Induced Expression of Brain Natriuretic Peptide Contributes to Its Increase in Patients with HFpEF.. <i>International Journal of Molecular Sciences</i> , 2022 , 23, | 6.3 | 0 |

| | | | |
|----|--|-----|---|
| 13 | Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction.. <i>Heart Failure Clinics</i> , 2022 , 18, 287-300 | 3.3 | ○ |
| 12 | Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study.. <i>ESC Heart Failure</i> , 2022 , | 3.7 | |
| 11 | Predictors for the Recovery of Left Ventricular Ejection Fraction in Myocardial Infarction. 1, | | 1 |
| 10 | Obesity and HFpEF. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3858 | 5.1 | ○ |
| 9 | Time-sensitive prognostic performance of an afterload-integrated diastolic index in heart failure with preserved ejection fraction: a prospective multicentre observational study. 2022 , 12, e059614 | | ○ |
| 8 | Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice. 2022 , 23, 9065 | | |
| 7 | Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. 2022 , 9, 256 | | 1 |
| 6 | Use of animal models to understand titin physiology and pathology. | | ○ |
| 5 | Baseline Characteristics, Risk Factors and Etiology of Heart Failure Among Patients Hospitalized at a Teaching Hospital in Somalia: Cross-Sectional Study. Volume 13, 63-71 | | ○ |
| 4 | Transthyretin Cardiac Amyloidosis. 2022 , 40, 541-558 | | ○ |
| 3 | Validity and utility of a vascular resistance-integrated diastolic index as a prognostic factor in heart failure with preserved ejection fraction. | | ○ |
| 2 | Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction: Technique Principles, Current Evidence, and Future Perspectives. Publish Ahead of Print, | | ○ |
| 1 | The Dilemma of Use of Anticoagulation in Patients With Heart Failure With Reduced Ejection Fraction and Sinus Rhythm: A Case Report and Literature Review. 2023 , | | ○ |